Taysha Gene Therapies (NASDAQ:TSHA) Issues Earnings Results

Taysha Gene Therapies (NASDAQ:TSHA) posted its quarterly earnings data on Tuesday. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02), Zacks reports.

Here are the key takeaways from Taysha Gene Therapies’ conference call:

• TSHA-102 demonstrated encouraging durability and breadth of benefit in REVEAL Part A: the response rate rose from 75% at three months to 100% at 12 months among 12 patients, with 310 functional gains reported across multiple Rett syndrome domains.
• Taysha completed dosing in the over-enrolled REVEAL pivotal trial with 17 patients and in the ASPIRE trial with four young children. The company expects to report six-month REVEAL interim data and FDA feedback on the potential BLA pathway in the first half of 2027, which could accelerate submission relative to waiting for 12-month data.
• A patient in the REVEAL pivotal trial experienced a moderate, treatment-related peripheral sensory neuropathy approximately six weeks after dosing and was briefly hospitalized. Taysha said the patient recovered substantially, characterized the event as a known AAV9-associated risk, and reported no severe treatment-related serious adverse events or dose-limiting toxicities among 33 treated patients.
• The company expanded its Catalent partnership for commercial manufacturing, with process performance qualification activities underway and the BLA-enabling campaign expected to be completed in the fourth quarter of 2026. Taysha said the FDA has found clinical and commercial lots analytically comparable to date, potentially allowing Part A data to support the regulatory submission.
• Taysha ended the quarter with $455.4 million in cash and cash equivalents, including $230 million in gross follow-on financing proceeds, and expects its resources to fund planned operations into the second half of 2028 and through potential BLA approval.

Taysha Gene Therapies Stock Performance

TSHA opened at $6.41 on Thursday. The company has a debt-to-equity ratio of 0.23, a current ratio of 14.04 and a quick ratio of 14.04. The business has a fifty day simple moving average of $6.09 and a 200 day simple moving average of $5.47. Taysha Gene Therapies has a 1 year low of $2.71 and a 1 year high of $7.30. The company has a market capitalization of $1.84 billion, a PE ratio of -15.26 and a beta of 1.22.

Insider Activity at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the firm’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the transaction, the insider directly owned 936,410 shares of the company’s stock, valued at approximately $5,843,198.40. This trade represents a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vestal Point Capital LP raised its position in shares of Taysha Gene Therapies by 150.0% in the fourth quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after buying an additional 8,250,000 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Taysha Gene Therapies by 2.3% during the fourth quarter. Goldman Sachs Group Inc. now owns 13,692,739 shares of the company’s stock worth $75,310,000 after buying an additional 309,031 shares in the last quarter. Vanguard Group Inc. grew its position in Taysha Gene Therapies by 17.9% during the third quarter. Vanguard Group Inc. now owns 12,849,613 shares of the company’s stock worth $42,018,000 after buying an additional 1,955,486 shares in the last quarter. Octagon Capital Advisors LP grew its position in Taysha Gene Therapies by 17.7% during the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after buying an additional 1,892,500 shares in the last quarter. Finally, State Street Corp increased its stake in Taysha Gene Therapies by 49.1% during the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock worth $59,345,000 after acquiring an additional 3,553,619 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Citizens Jmp reaffirmed a “market outperform” rating and issued a $11.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, July 2nd. BMO Capital Markets boosted their price target on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $12.77.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.